ANI Pharmaceuticals shareholders approve Amended 2022 Stock Plan, re-elect directors

ANI PHARMACEUTICALS INC

At May 21 annual meeting, all eight director nominees elected; Thomas Haughey received 14.8M for, 2.1M against.
Shareholders ratified EisnerAmper as auditor for FY2024: 18.0M for, 56.7K against.
Advisory say-on-pay approved: 16.1M for, 762.7K against, 1.2M broker non-votes.
Amended 2022 Stock Incentive Plan approved: 16.0M for, 871.2K against, 1.2M broker non-votes.
Plan increases equity pool; forms for director (1-yr cliff) and employee (4-yr graded) restricted stock filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.